Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors.

"Competing interests ABE-K reports honoraria from ABL bio, Agenus, AstraZeneca/MedImmune, Bayer, Bristol-Myers Squibb, CytomX Therapeutics, EISAI, EMD Serono, Exelixis, Gilead Sciences, Merck, Pieris Pharmaceuticals, QED Therapeutics, Roche/Genentech, SERVIER, and Tallac Therapeutics; consulting or advisory board roles with BL Bio, Agenus, AstraZeneca/MedImmune, Bayer, Bristol-Myers Squibb, CytomX Therapeutics, Eisai, EMD Serono, Exelixis, Gilead Sciences, Merck, Pieris Pharmaceuticals, QED Therapeutics, Roche, SERVIER, and Tallac Therapeutics; and institutional research funding from Astex Pharmaceuticals, AstraZeneca, Fulgent Genetics, and GSK. JC, TC, NR, CR, and AT are employees of and hold equity in GSK. PN is a former employee of and holds equity in GSK. TN is a former employee of GSK. IG-L reports consulting or advisory board roles for SOTIO, Kanaph, JAZZ, and ONCXer, and institutional research funding from Novartis, Bayer, Bristol-Myers Squibb, Pfizer, MedImmune, Lilly, Incyte, GSK, Tolero Pharmaceuticals, BridgeBio Pharma, Jacobio, Repare Therapeutics, and Sumitomo Dainippon Pharma Oncology. EC reports a leadership role in START, Pharma Mar, EORTC, Sanofi, BeiGene and Novartis; stock and other ownership interests with Oncoart Associated and START; honoraria from HM Hospitals Group; consulting or advisory roles to Adcendo, Amunix, Anaveon, AstraZeneca/MedImmune, Bristol-Myers Squibb, Chugai Pharma, Elevation Oncology, Ellipses Pharma, Genmab, Janssen-Cilag, MonTa Biosciences, MSD Oncology, Nanobiotix, Nouscom, Novartis, OncoDNA, PharmaMar, Roche/Genentech, Servier, Syneos Health, T-Knife, and TargImmune Therapeutics; research funding START, and GSK; and President and Founder of Foundation role for INTHEOS (Investigational Therapeutics in Oncological Sciences). JR reports non-financial support and reasonable reimbursement for travel from the European Society for Medical Oncology; consulting and travel fees and advisory board membership for Peptomyc, Kelun Pharmaceuticals/Klus Pharma, Ellipses Pharma, Molecular Partners, and IONCTURA; consulting fees from Vall d’Hebron Institute of Oncology/Ministero De Empleo Y Seguridad Social, Chinese University of Hong Kong, Boxer Capital, LLC, and Tang Advisors, LLC; research funding for him or his institution from Blueprint Medicines, Black Diamond Therapeutics, Merck Sharp & Dohme, Hummingbird, Yingli, and Vall d’Hebron Institute of Oncology/Cancer Core Europe; serving as an investigator in clinical trials or clinical research funding to him or his institution from Novartis, Spectrum Pharmaceuticals, Symphogen, BioAlta, Pfizer, GenMab, CytomX, Kelun-Biotech, Takeda-Millenium, GSK, Taiho, Roche Pharmaceuticals, Hummingbird, Yingli, Bicycle Therapeutics, Merus, Curis, Bayer, AadiBioscience, Nuvation, ForeBio, BioMed Valley Discoveries, Loxo Oncology, Hutchinson MediPharma, Cellestia, Deciphera, Ideaya, Amgen, Tango Therapeutics, Mirati Linnaeus Therapeutics, and Cancer Core Europe. He holds no patents, nor does he have close relationships, academic rivalries, political party memberships, or religious convictions that would affect the content of this manuscript. BT reports consulting fees from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Ipsen, IQVIA, Janssen-Cilag, Merck Sharp & Dohme, Novartis, Pfizer/EMD Serono, Roche, Sanofi, and Tomar; research funding from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, GSK, Ipsen, Janssen-Cilag, Merck Sharp & Dohme, and Pfizer; honoraria from Amgen, Astellas, Bristol-Myers Squibb, Janssen-Cilag, Sanofi, and Tolmar; and travel reimbursement from Amgen and Astellas. He reports personal fees from IQVIA, Sanofi, Tolmar, Novartis, and Roche. PJO’D reports research support from Pfizer, Genentech, GSK, BMS, AZ, Five Prime, FortySeven, Merck, Syndax, RRI, Novartis, Celgene, Incyte, Lilly/Imclone, array, H3 Biomedicine, Taiho, Minneamrata, Pharmacyclics/Abbvie, and Mirati; consulting relationships with Genentech and Array, and has provided expert testimony for Bayer and Lilly. He reports no stock or patents or other relationships that would affect the content of this manuscript. AC has served as a consultant for Synergy; received authorship royalties from UpToDate; and his institution has received research support on his behalf from Alexion, Bayer, Novartis, Novo Nordisk, Pfizer, Sanofi, Spark, and Takeda. AR reports grants from Merck, Bristol-Myers Squibb, Novartis, Karyopharm, Boston Biochemical, Deciphera, Genentech, Roche, Pfizer, Medimmune, Eli Lilly, Boehringer Ingelheim, Entremed/CASI Pharmaceuticals, Amgen, Champions Oncology, Iterion, Blueprint, Adaptimmune, Neoleukin, and GSK during the conduct of the study, as well as personal fees from Eli Lilly, Boehringer Ingelheim, Merck, Adaptimmune, Bayer, Medison, and GSK outside the submitted work."

"Funding Authors who are or were employees of GSK contributed to the design of the study, analysis of the data, and in the decision to publish. Funding for this study (NCT03666988 available from www.clinicaltrials.gov) was provided by GSK. Open access funding provided by SCELC, Statewide California Electronic Library Consortium."

"Trial registration number NCT03666988. "